Masimo - softFlow 50

TNI softFlow® 50

For Spontaneously Breathing Adult Patients in Hospital and Home-care* Environments

  • Respiratory support delivered through a soft nasal cannula interface
  • Adjustable flow rate from 10 to 50 L/min to meet the inspiratory flow needs of the patient
  • Warmed humidification of air/oxygen to help provide therapy comfort and aid in mucus clearance1,2
  • Ability to supplement with 0-20 L/min of oxygen depending on patient requirements
  • Integrated flow driver provides flow, without the need for dedicated hospital pneumatic systems, in multiple clinical and home settings
  • Condensate-free air/oxygen flow for compliant therapy
  • The system identifies the type of nasal cannula interface and breathing circuit on connection, workflows through automated configuration

Performance Data

  • Adjustable flow rate: 10 to 50 L/min +/- 2%, adjustable in 0.5 L/min steps
  • Supplemental oxygen support: 0-20 L/min, with FiO2 indicator integrated into the display
  • Adjustable humidity: dew point from 30° - 37°C, adjustable in 1°C steps
  • Integrated micro-particle filter
  • Variety of nasal cannula prongs to suit a wide range of patient applications

Hospital Model

 
  • Replaceable disposable breathing filter (Bacterial efficiency >99.999%) to reduce risk of cross-contamination between patients
  • Autofilling humidification water chamber – no need to manually check and refill humidity chamber between uses

Home-care Model

 
  • Provides consistent high-flow nasal cannula therapy in the home setting
  • Large 600 mL humidification water chamber to accommodate longer use between refills
  • Humidification system compatible with drinking or demineralized water, for ease of sourcing

References:

  1. 1.

    Hasani, A et al. Chron Respir Dis 5, no. 2 (2008): 81-86.

  2. 2.

    Roca, O et al. Respir Care 55, no. 4 (2010): 408-413.

  3. *FDA cleared for use in hospitals and long term facilities. Available for home care use in the US under COVID-19 provisions.

RESOURCES

 

Masimo - Product Information - TNI softFlow 50

Product Information

Use of High-Flow Nasal Therapy on Patients with Suspected or Confirmed COVID-19 COVID-19 is a highly contagious disease, and virtually all forms of respiratory support, including high-flow nasal therapy, pose some risk of disease transmission. The U.S. Food and Drug Administration has stated that ventilating patients with communicable diseases using noninvasive devices without a filtered seal from atmosphere may contaminate room air and increase risk of transmission, and that this risk may be exacerbated by high-flow nasal therapy systems. Some clinicians have also suggested that the use of high flow nasal therapy may facilitate the spread of COVID-19 or other communicable diseases through aerosolization of pathogens. If high-flow nasal therapy is used to treat patients with COVID-19 or other communicable diseases, appropriate precautions should be taken, such as placing a mask over the nose and mouth of suspected and infected patients while on high-flow nasal therapy, isolating patients in negative pressure rooms, and providing caregivers with appropriate personal protective equipment specified for aerosol-generating procedures; however, these precautions cannot guarantee that diseases will not be transmitted to caregivers or others.

TNI softFlow 50 is not licensed for sale in Canada.

For professional use. See instructions for use for full prescribing information including indications, contraindications, warnings and precautions. Caution: Federal (USA) law restricts this device to sale by or on the order of a physician.

PLCO-003718/PLM-12264A-0420